SIRT1 and Parkinson disease: Preclinical studies across AD, PD, HD, and ALS models demonstrate consistent benefits in synaptic integrity, neurotrophic signalling, and proteostasis, mediated by regulators such as BDNF, SIRT1, mTOR, and gut-derived metabolites like SCFAs and BHB.